{
    "clinical_study": {
        "@rank": "141401", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration)."
            }, 
            {
                "arm_group_label": "Treatment B", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration)."
            }, 
            {
                "arm_group_label": "Treatment C", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration)."
            }, 
            {
                "arm_group_label": "Treatment D", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration)."
            }
        ], 
        "brief_summary": {
            "textblock": "To estimate the effect of food on the pharmacokinetics and relative bioavailability of\n      oxycodone following oral administration of single 40 mg doses of PF 00345439 Formulation K\n      taken whole or after chewing in healthy volunteers.  We have described below the two cohorts\n      each with two arms in this crossover study by listing them as four Arms/Groups in order to\n      capture the differences between the cohorts prior to the crossover and after the crossover.\n      14 participants are planned for the first cohort and 18 participants are planned for the\n      second cohort."
        }, 
        "brief_title": "Effects of Food on Oxycodone Pharmacokinetics in Healthy Volunteers", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and/or female subjects between 18 and 55 years of age\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant disease.\n\n          -  Positive urine drug test"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02117583", 
            "org_study_id": "B4501039"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment A", 
                "description": "One capsule of 40 mg PF-00345439 Formulation K, taken whole, single dose, under fasting conditions", 
                "intervention_name": "Oxycodone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment B", 
                "description": "One capsule of 40 mg PF-00345439 Formulation K, taken whole, single dose, under fed conditions", 
                "intervention_name": "Oxycodone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment C", 
                "description": "One capsule of 40 mg PF-00345439 Formulation K, Chewed, single dose, under fasting conditions", 
                "intervention_name": "Oxycodone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment D", 
                "description": "One capsule of 40 mg PF-00345439 Formulation K, Chewed, single dose, under fed conditions", 
                "intervention_name": "Oxycodone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Oxycodone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "pharmacokinetics", 
            "relative bioavailability", 
            "food effects", 
            "oxycodone"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4501039&StudyName=Effects%20of%20Food%20on%20Oxycodone%20Pharmacokinetics%20in%20Healthy%20Volunteers"
        }, 
        "number_of_arms": "4", 
        "official_title": "An Open-Label, Randomized, 2-Cohort, Single-Dose, Crossover Study To Estimate The Effects Of Food On Oxycodone Pharmacokinetics Following Oral Administration Of 40 Mg Doses Of Pf 00345439 Formulation K Taken Whole Or After Chewing In Healthy Volunteers", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).", 
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]", 
                "safety_issue": "No", 
                "time_frame": "0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02117583"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48"
            }, 
            {
                "measure": "Concentration at time 24 hours (C24)", 
                "safety_issue": "No", 
                "time_frame": "0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}